12 November 2018
Medicines Discovery Catapult and the Medical Research Council (MRC) Centre for Drug Safety Science (CDSS) have agreed a memorandum of understanding to combine their academic and industry expertise developing next generation 3D human cell models and creating robust cellular platforms.
The purpose of the collaboration is to identify and establish projects focused on the development of human 3D cell models and robust cellular platforms.
CDSS brings extensive experience in pre-clinical safety and in the establishment of new models and techniques that are clinically relevant. Medicines Discovery Catapult brings drug discovery expertise capabilities and a rapidly developing suite of cutting-edge research technologies as well as a close relationship with the life science and technology communities.
The partnership will combine the cell biology and pharmacology expertise of CDSS with Medicines Discovery Catapult’s organ-on-a-chip capabilities to explore ground-breaking opportunities to connect together multiple organ models to further improve patient relevance.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Four cancer centers opened in Russia in 2023
26 April 2024
Russia and the UAE can simplify the drug registration process
26 April 2024
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024